|
|
 |
|
Viewing report
|
|
|
|
The New Trends of Global Pharmaceutical Outsourcing: New Developments in Strategy, Market, Service and Technology
JZMed Inc, Oct 2011, Pages: 215
It has been widely recognized that the global pharmaceutical industry is currently experiencing dynamic change. Primarily due to the low success rate of drug R&D, all world pharmaceutical companies are currently remodeling their traditional drug R&D. They are now focusing on de-risking their R&D effort through utilizing the external resources. The global competitive environment has also forced them to further streamline their manufacturing operation. The cost-reduction strategy is thus being vigorously pursued by all drug companies. In the meantime, all major pharma companies have also realized that they are no longer able to hold everything in house. A networked partnership that best utilizes the external resources has thus evolved in the world pharmaceutical industry.
All these actions have been resulting in the rapid increase in outsourcing demand in almost all aspects of today’s world pharmaceutical industry. As part of the world pharmaceutical industry, the world pharmaceutical outsourcing industry is thus also experiencing dramatic changes at present.
The report, “The New Trends of Global Pharmaceutical Outsourcing – New Developments in Strategy, Market, Service and Technology”, published by JZMed, Inc, a world renowned market research firm specialized in pharmaceutical outsourcing industry, has provided the unique insights into the current development states of this industry. The report is designed specifically to provide company executives, decision makers, business strategists and all other professionals of both drug companies and outsourcing service providers as well as financial investment firms the clear insights of the latest development trends in the global pharmaceutical, biotechnology and outsourcing service industries, including the detailed insights of how the global pharma outsourcing industry is currently developing, what outsourcing strategies are evolving, what new service models and new technologies have been developed, etc.
Based on the in-depth analysis of a series of growth drivers and resistors that will affect the future development of the global pharma outsourcing industry, the report further depicted a clear future development picture of the industry in the following few years, including the future market growth forecasts by 2015 of the entire industry and each of its service sectors.
The report is a must-read book to global pharmaceutical and biotechnology companies seeking outsourcing opportunities, outsourcing service providers looking for their future development direction, venture capital investors interested in the investment opportunities in the global pharma outsourcing industry, and even the government agencies that are interested in learning the current and future developments of the global pharmaceutical outsourcing industry.
Highlights of the Key Findings of the Report
- Under the high pressure of containing the fixed cost, all drug companies are currently reducing their internal capacities in R&D, manufacturing and even marketing. To replace the work left but still need to be done, they are thus increasing the outsourcing proportion in all aspects of their daily operation.
- The global competitive environment is forcing all drug companies to remodel their traditional drug R&D operation. They are de-risking their R&D effort through utilizing the external resources. Almost all drug companies have now established special internal operation units to specifically manage the relationship with all companies they partner or collaborate with. In fact, outsourcing now includes partnership, collaboration, alliance, or any type of their combinations. An integrated virtual operation model is thus quietly evolving in the global pharmaceutical and biotechnology industries and has now been recognized as their new operation standard. The new model is helping drug companies quickly reduce the fixed cost, significantly improve operation flexibility, and immediately have access to the latest technologies and talents around the world. It has become the effective way to help the pharmaceutical industry overcome the difficulties and solve the problems that have been seriously troubling them for years.
- Meanwhile, to increase productivity and efficiency, both drug companies and outsourcing service providers are striving to make improvements in every aspect of drug R&D and manufacturing process. Many CROs/CMOs have put enormous efforts to develop new technologies and services in order to better serve their clients and, meanwhile, to differentiate them from their peer competitors. A series of new technologies such as biomarkers, molecular imaging and companion diagnostics, etc., and new services such as antibody library screening, genomic testing and cell-line development, etc., have thus been developed and become available to all drug companies.
- Moreover, to offset the revenue shortage from the innovative small molecule drugs, almost all pharma companies are now putting increasing effort on the development of innovative biologic products, including raising R&D investment in this area and in-licensing early stage novel biologic drugs from biopharma companies around the world. As drug companies, both large and small, are gradually shifting their focus from small molecule drugs to macro-compounds, the outsourcing service demands for biopharmaceutical products, both R&D and manufacturing, are thus rapidly growing.
- At the same time, all global major pharma companies also increasingly pay serious attention to the emerging markets. They are currently not only focusing on expanding their market space in the emerging countries, but also outsourcing more costly R&D and manufacturing work to these regions, especially for small molecule drugs. Consequently, the emerging countries are rapidly gaining strengths in both R&D and manufacturing of small molecule drugs.
Why You Should Have This Report
- After reading the report, readers will have become immediately clear about what is really going on in the global pharmaceutical outsourcing industry and known which models your company should adopt and what strategies you should take in order to better position your company in the highly competitive global market.
- The report will give you an in-depth analysis on the current bottlenecks in drug R&D, challenges facing the global pharmaceutical and biotechnology industries, and the strategies both major pharma and biotech companies are currently implementing to overcome these difficulties.
- Moreover, you will gain detailed insights on the current development states of each service sector of the global pharma outsourcing industry as well as the strategies the global drug companies are currently taking in each stage of their R&D and manufacturing process. It will thus help you better understand the future development directions of the entire global pharma outsourcing industry and each of its service sectors.
- The report will thus help you figure out the clear trends of the latest developments in the global pharma outsourcing industry, including the market growth trends, new outsourcing strategies being implemented, new outsourcing services and technologies being developed, and new outsourcing destinations currently evolving, etc.
- The report will also facilitate you learning both the current market values and the future growth potentials of the global pharmaceutical outsourcing industry, including each of its service sectors.
|
|
|
|
